I’m referring to the FDA advisory panel for Ocaliva rather than the FDA decision per se.
Advisory panels discuss label-related issues, but they don’t typically undertake a formal vote on the label. On the main question of whether the FDA should approve Ocaliva for NASH, I would say there’s only a 25% chance that the panel endorses Ocaliva by a 70/30-or-better margin.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.